» Articles » PMID: 11274306

Risk of Dementia in Parkinson's Disease: a Community-based, Prospective Study

Overview
Journal Neurology
Specialty Neurology
Date 2001 Mar 29
PMID 11274306
Citations 200
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To calculate the incidence of and determine possible risk factors for dementia in PD.

Background: Dementia has important clinical consequences for patients with PD and their caregivers, but the incidence is unknown.

Methods: A population-based cohort of nondemented patients with PD (n = 171) from the county of Rogaland, Norway, was assessed at baseline and 4.2 years later with a comprehensive evaluation of motor, cognitive, and neuropsychiatric symptoms. The diagnosis of dementia was made according to the Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised (DSM-III-R) criteria, based on interview of the patient and a caregiver, cognitive rating scales, and neuropsychologic tests. A representative sample of 3,062 nondemented elderly subjects without PD served as control group.

Results: Forty-three patients with PD were demented at follow-up evaluation, equivalent to an incidence rate of 95.3 per 1,000 person-years (95% CI, 68.2 to 122.0). The risk for the development of dementia in patients with PD relative to the control subjects after adjusting for age, sex, and education was 5.9 (95% CI, 3.9 to 9.1). Predictive factors at baseline for dementia in PD in addition to age were Hoehn & Yahr score >2 (OR, 3.4; 95% CI, 1.3 to 8.6) and Mini-Mental State Examination score < 29 (OR, 3.3; 95% CI, 1.3 to 8.2).

Conclusions: Patients with PD have an almost sixfold increased risk for becoming demented compared with subjects without PD.

Citing Articles

Early Detection and Management of Cognitive Impairment in Parkinson's Disease: A Predictive Model Approach.

Li L, Tang S, Hao B, Gao X, Liu H, Wang B Brain Behav. 2025; 15(3):e70423.

PMID: 40079619 PMC: 11904965. DOI: 10.1002/brb3.70423.


A Multi-omics Framework Based on Machine Learning as a Predictor of Cognitive Impairment Progression in Early Parkinson's Disease.

Luo Y, Xiang Y, Liu J, Hu Y, Guo J Neurol Ther. 2025; 14(2):643-658.

PMID: 39985630 PMC: 11906927. DOI: 10.1007/s40120-025-00716-y.


Olfactory dysfunction as potential biomarker in neurodegenerative diseases: a narrative review.

De Cleene N, Schwarzova K, Labrecque S, Cerejo C, Djamshidian A, Seppi K Front Neurosci. 2025; 18():1505029.

PMID: 39840019 PMC: 11747286. DOI: 10.3389/fnins.2024.1505029.


The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases.

Sarallah R, Jahani S, Khaboushan A, Moaveni A, Amiri M, Zolbin M Brain Behav Immun Health. 2025; 43():100932.

PMID: 39834554 PMC: 11743895. DOI: 10.1016/j.bbih.2024.100932.


Plasma alpha-synuclein predicts cognitive impairment in Parkinson's disease: a systematic review and meta-analysis.

Zhu Z, Cordato D, Chen R, Xu Y, Shulruf B, Chan D J Neurol. 2025; 272(2):124.

PMID: 39812682 DOI: 10.1007/s00415-024-12871-7.